| Primary |
| Pneumonia |
12.6% |
| Acinetobacter Infection |
8.8% |
| Klebsiella Infection |
6.7% |
| Cellulitis |
6.5% |
| Constipation |
6.5% |
| Hypertension |
6.5% |
| Sepsis |
6.3% |
| Pathogen Resistance |
4.8% |
| Abdominal Infection |
4.6% |
| Candidiasis |
4.4% |
| Osteomyelitis |
4.0% |
| Bacteraemia |
3.8% |
| Staphylococcal Infection |
3.8% |
| Peritonitis |
3.6% |
| Abdominal Abscess |
3.1% |
| Infection |
3.1% |
| Multiple-drug Resistance |
2.9% |
| Pain |
2.9% |
| Soft Tissue Infection |
2.7% |
| Analgesic Effect |
2.5% |
|
| Death |
13.3% |
| Drug Ineffective |
10.8% |
| Vomiting |
9.6% |
| Pancreatitis |
9.0% |
| Infection |
6.0% |
| Pathogen Resistance |
6.0% |
| Clostridial Infection |
4.8% |
| Thrombocytopenia |
4.8% |
| Jaundice |
4.2% |
| Renal Failure Acute |
4.2% |
| Diarrhoea |
3.6% |
| Sepsis |
3.6% |
| Drug Resistance |
3.0% |
| Septic Shock |
3.0% |
| Electrocardiogram Qt Prolonged |
2.4% |
| Multi-organ Failure |
2.4% |
| Pancreatitis Necrotising |
2.4% |
| Pulmonary Embolism |
2.4% |
| Thrombocythaemia |
2.4% |
| Lung Abscess |
1.8% |
|
| Secondary |
| Pneumonia |
10.1% |
| Acinetobacter Infection |
9.3% |
| Abdominal Infection |
9.0% |
| Klebsiella Infection |
8.7% |
| Bacteraemia |
6.6% |
| Sepsis |
5.7% |
| Drug Use For Unknown Indication |
5.4% |
| Antibiotic Therapy |
5.2% |
| Staphylococcal Infection |
5.2% |
| Multiple-drug Resistance |
4.4% |
| Aspergillosis |
3.8% |
| Product Used For Unknown Indication |
3.5% |
| Urinary Tract Infection |
3.4% |
| Enterobacter Infection |
3.2% |
| Pathogen Resistance |
3.0% |
| Blood Cholesterol Increased |
2.8% |
| Muscle Spasms |
2.8% |
| Staphylococcal Bacteraemia |
2.7% |
| Autoimmune Hepatitis |
2.6% |
| Peritonitis |
2.6% |
|
| Death |
21.8% |
| Drug Ineffective |
12.6% |
| Multi-organ Failure |
7.5% |
| Respiratory Failure |
6.9% |
| Pathogen Resistance |
6.3% |
| Infection |
5.7% |
| Septic Shock |
5.2% |
| Shock Haemorrhagic |
4.6% |
| Sepsis |
4.0% |
| Drug Resistance |
2.9% |
| Pneumonia Klebsiella |
2.9% |
| Rash Macular |
2.9% |
| Acinetobacter Infection |
2.3% |
| Clostridial Infection |
2.3% |
| Infusion Site Irritation |
2.3% |
| Klebsiella Bacteraemia |
2.3% |
| Splenic Infarction |
2.3% |
| International Normalised Ratio Increased |
1.7% |
| Jaundice |
1.7% |
| Pancreatitis |
1.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
44.3% |
| Drug Use For Unknown Indication |
17.8% |
| Prophylaxis |
4.2% |
| Acute Myeloid Leukaemia |
3.9% |
| Infection |
3.2% |
| Acute Lymphocytic Leukaemia |
3.0% |
| Pneumonia |
3.0% |
| Pain |
2.4% |
| Hypertension |
2.1% |
| Peritonitis |
2.1% |
| Antibiotic Prophylaxis |
1.8% |
| Febrile Neutropenia |
1.8% |
| Sepsis |
1.8% |
| Infection Prophylaxis |
1.4% |
| Post Procedural Infection |
1.4% |
| Pyrexia |
1.4% |
| Stem Cell Transplant |
1.4% |
| Multiple Myeloma |
1.3% |
| Prophylaxis Against Graft Versus Host Disease |
1.1% |
| Atypical Mycobacterial Infection |
1.0% |
|
| Sepsis |
17.5% |
| Weight Decreased |
12.7% |
| Treatment Failure |
10.3% |
| Drug Ineffective |
6.3% |
| Renal Failure Acute |
6.3% |
| Septic Shock |
4.8% |
| Postoperative Wound Infection |
4.0% |
| Renal Failure |
4.0% |
| Leukopenia |
3.2% |
| Pancreatitis |
3.2% |
| Rhabdomyolysis |
3.2% |
| Urinary Retention |
3.2% |
| Vomiting |
3.2% |
| White Blood Cell Count Decreased |
3.2% |
| White Blood Cell Count Increased |
3.2% |
| Apnoea |
2.4% |
| Death |
2.4% |
| Hepatotoxicity |
2.4% |
| Infection |
2.4% |
| Multi-organ Failure |
2.4% |
|
| Interacting |
| Immunosuppression |
35.3% |
| Enterococcal Infection |
11.8% |
| Osteomyelitis Chronic |
11.8% |
| Prophylaxis Against Transplant Rejection |
11.8% |
| Sepsis |
11.8% |
| Anaesthesia |
5.9% |
| Pneumonia Staphylococcal |
5.9% |
| Septic Shock |
5.9% |
|
| Neurological Symptom |
33.3% |
| Blood Creatinine Increased |
16.7% |
| Immunosuppressant Drug Level Increased |
16.7% |
| Pancreatitis Necrotising |
16.7% |
| Platelet Count Decreased |
16.7% |
|
